Released Mar 10, 2022, after the close
10-K filed Mar 11, 2022, 70 days after period end · 0001564590-22-009855
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$60.26M-$60.26M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$62,889,000N/M
Operating Cash Flowderived-$19,362,000N/M
Free Cash Flowderived-$19,380,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020 | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | — | $1.04M | $4.77M | $3.74M |
| Net Income | -$60.26M | -$39.42M | -$27.08M | -$26.16M |
| EPS Diluted | — | -$1.11 | -$0.99 | -$1.03 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR